EHA 2019 – Global Blood faces sickle cell questions
More data with voxelotor shouldn’t hurt the project’s bid for accelerated approval, but there are still doubts about its effect on a harder patient outcome.
EHA 2019 – turnaround puts Arqule in the takeover frame
A key update confirms ARQ 531 as the leading contender to treat patients who relapse on Imbruvica or Calquence.
ADA 2019 – another gut punch for Lilly
Lilly is still trying to find a therapeutic window following gastrointestinal issues with its brightest pipeline hope, the GIP/GLP1 agonist tirzepatide.
ADA 2019 – Provention claims success where Lilly failed
The company’s teplizumab delays development of type 1 diabetes, but Lilly’s failure with the same project nine years earlier casts a long shadow.
ADA 2019 – Rewind makes Lilly’s Trulicity look average
Less than emphatic cardiovascular outcomes data leave Lilly looking vulnerable to Novo Nordisk’s competing drugs.
Asco 2019 event analyser – low-key meeting belies some huge stock moves
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Asco 2019 – KRAS chase heats up with Amgen data
Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.
Asco 2019 – Macrogenics builds a case for margetuximab
Demonstrating an overall survival benefit remains crucial for Macrogenics’ anti-Her2 antibody margetuximab, for regulatory approval and any partnering deals alike.
Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.